Jazz Pharmaceuticals (JAZZ) Q4 FY25 earnings call: guidance and Q&A

Clarification on Xywav's flat to mid-single-digit growth guidance for 2026, specifically regarding the impact of generic high sodium oxybate products in H1 vs. H2 and potential payer concessions.

Management confirmed that Xywav enters 2026 well-positioned with strong momentum and payer contracts. They expect minimal impact from generics in H1 2026, but anticipate increased competitive dynamics in H2 due to generics building volume and potential entry of new wake-promoting agents. Xywav's differentiation as the only low-sodium oxybate and FDA-approved IH treatment is expected to drive continued growth, particularly from the IH segment.

“We also now have better line of sight into the timing of entry for generic high sodium oxybate products where it appears that now we've got two as we speak, that are in the process of having their launch that could have occurred as early as December 31 of last year, but is occurring now.”

asked by Jason Gerberry · answered by Philip Johnson

Inquiry about the background, mechanism of action, and preclinical data for JZP047, specifically if it's cannabinoid-related and its focus on absence seizures.

Management stated that JZP047 is not cannabinoid-related but a novel chemical entity discovered and developed in-house. They have strong preclinical data supporting its use in absence epilepsy, which will be the initial focus. A Phase I healthy volunteer trial has been initiated to gather safety and exposure information before moving to patient populations.

“I can say that it's not in the cannabinoid space. It's a novel chemical entity that we developed -- discovered and developed at Jazz. We have strong preclinical data, we believe in absence epilepsy and that will be our initial focus of development.”

asked by Marc Goodman · answered by Robert Iannone

Details on the post-HER2 breast cancer population for zanidatamab, including market size, typical treatments, potential penetration, and pricing strategy.

Management sees the treatment landscape evolving with HER2 moving to frontline, creating an opportunity for zanidatamab in the subsequent lines of therapy (essentially third-line plus). They estimate 150,000 HER2-positive breast cancer patients in their served markets. It's too early to comment on specific pricing strategy, but the EmpowHER study is expected to complete enrollment in H1 2027 and read out in late 2027/early 2028.

“We said there are about 150,000 patients with HER2-positive breast cancer in the markets that we serve. And we think it would be the first to have data in this positive HER2 setting.”

asked by Anastasia Parafestas · answered by Robert Iannone

Possibility of payers renegotiating Xywav contracts or implementing step edits/restrictions due to generic entry, and how Jazz would respond.

Management acknowledges the possibility of payers approaching them for renegotiation if generics gain significant market share, but highlights that the material rebates on Xywav would make payers hesitant to walk away. They also emphasize Xywav's strong differentiation as the only low-sodium option, which resonates with physicians and patients, especially given comorbidities. They have seen physicians motivated to navigate step edits for Xywav in the past, reinforcing their belief in its unique value proposition.

“Even with a step edit, we believe that there will be a strong commitment from health care providers to move through those step edits to get to low sodium Xywav.”

asked by David Hoang · answered by Samantha Pearce

Assessment of Modeyso's strong early launch, confidence in the >$500 million U.S. sales guidance, and the role of the ACTION study in achieving that guidance.

Management is delighted with Modeyso's early launch, driven by high unmet need and awareness. They are increasingly confident in the >$500 million peak sales opportunity, which assumes a positive outcome from the ACTION study. A successful ACTION study would allow earlier use of the product (immediately after radiotherapy), which is crucial for reaching the peak sales target. They are still gathering data on real-world treatment duration and epidemiology.

“That does assume that we hit on the first-line action study to achieve that because what that means is that the product will get used earlier, immediately after radiotherapy as opposed to waiting for progression, which is the label that we currently have.”

asked by Brian Skorney · answered by Samantha Pearce

Comfort level with leveraging the balance sheet again for significant acquisitions, given past deleveraging efforts, and the preferred size/type of transactions.

Management confirmed their comfort with leveraging the balance sheet for compelling transactions that benefit patients and create shareholder value, noting their current net debt/EBITDA is around 1.5x. They expect debt to be a smaller component of capitalization over the long term, but anticipate a 'sawtooth' pattern with peaks for M&A transactions. They are focused on licensing and M&A opportunities within their current franchises (sleep, epilepsy, oncology) and other rare disease areas.

“We certainly have deleveraged substantially on a net basis, down to about 1.5 turns of EBITDA at the end of 2025. And we do have the ability to go ahead and lever up for a transaction or a series of transactions.”

asked by Joseph Thome · answered by Philip Johnson